APA (7th ed.) Citation

Aslanyan, M. G., Kroeze, L. I., Langemeijer, S. M. C., Koorenhof-Scheele, T. N., Massop, M., van Hoogen, P., . . . Marijt, E. W. A. (2014). CLINICAL AND BIOLOGICAL IMPACT OF TET2 MUTATIONS AND EXPRESSION IN YOUNGER ADULT AML PATIENTS TREATED WITHIN THE EORTC/GIMEMA AML-12 CLINICAL TRIAL. Romanian Journal of Oncology & Hematology, 2(4), 190. https://doi.org/10.1007/s00277-014-2055-7

Chicago Style (17th ed.) Citation

Aslanyan, Mariam G., et al. "CLINICAL AND BIOLOGICAL IMPACT OF TET2 MUTATIONS AND EXPRESSION IN YOUNGER ADULT AML PATIENTS TREATED WITHIN THE EORTC/GIMEMA AML-12 CLINICAL TRIAL." Romanian Journal of Oncology & Hematology 2, no. 4 (2014): 190. https://doi.org/10.1007/s00277-014-2055-7.

MLA (9th ed.) Citation

Aslanyan, Mariam G., et al. "CLINICAL AND BIOLOGICAL IMPACT OF TET2 MUTATIONS AND EXPRESSION IN YOUNGER ADULT AML PATIENTS TREATED WITHIN THE EORTC/GIMEMA AML-12 CLINICAL TRIAL." Romanian Journal of Oncology & Hematology, vol. 2, no. 4, 2014, p. 190, https://doi.org/10.1007/s00277-014-2055-7.